Literature DB >> 19475497

Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.

Caterina Mian1, Susi Barollo, Laura Zambonin, Gianmaria Pennelli, Paolo Bernante, Maria Rosa Pelizzo, Davide Nacamulli, Franco Mantero, Maria Elisa Girelli, Giuseppe Opocher.   

Abstract

RET codon 609 point mutations are rare and may predispose to aggressive medullary thyroid carcinoma (MTC). In a kindred with 15 carriers of the Cys609Ser RET mutation we observed no MTC before 17 years of age, no lymph node metastases before 30 years and no distant metastases before 60 years. Two patients developed pheochromocytoma and one had primary hyperparathyroidism as the first sign of the syndrome. In conclusion, at variance from what already known, in this large kindred the Cys609Ser RET mutation predispose to a scarcely aggressive, highly penetrant MTC and a low penetrance of pheochromocytoma and primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475497     DOI: 10.1007/s10689-009-9250-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  11 in total

1.  Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.

Authors:  William B Kinlaw; Sarah M Scott; Robert A Maue; Vincent A Memoli; Robert D Harris; Gilbert H Daniels; Donna M Porter; Dorothy R Belloni; Edward T Spooner; Manfred M Ernesti; Walter W Noll
Journal:  Clin Endocrinol (Oxf)       Date:  2005-12       Impact factor: 3.478

2.  A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma.

Authors:  O Fattoruso; L Quadro; A Libroia; U Verga; G Lupoli; E Cascone; V Colantuoni
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

3.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

4.  Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference.

Authors:  H R Keiser; M A Beaven; J Doppman; S Wells; L M Buja
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

5.  Multiple endocrine neoplasia 2A syndrome: Surgical management.

Authors:  S Simon; M Pavel; J Hensen; J Berg; H P Hümmer; R Carbon
Journal:  J Pediatr Surg       Date:  2002-06       Impact factor: 2.545

6.  The risk of medullary thyroid carcinoma in patients with Hirschsprung's disease.

Authors:  Richard Skába; Sárka Dvoráková; Eliska Václavíková; Petr Vlcek; Miroslava Frantlová; Bela Bendlová
Journal:  Pediatr Surg Int       Date:  2006-12       Impact factor: 1.827

Review 7.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

8.  Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.

Authors:  T Iwashita; M Kato; H Murakami; N Asai; Y Ishiguro; S Ito; Y Iwata; K Kawai; M Asai; K Kurokawa; H Kajita; M Takahashi
Journal:  Oncogene       Date:  1999-07-01       Impact factor: 9.867

9.  Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer.

Authors:  Attila Patocs; Izabella Klein; Aniko Szilvasi; Peter Gergics; Miklos Toth; Zsuzsa Valkusz; Erzsebet Forizs; Peter Igaz; Yousuf Al-Farhat; Attila Tordai; Andras Varadi; Karoly Racz; Olga Esik
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

10.  Familial prevalence and age of RET germline mutations: implications for screening.

Authors:  Andreas Machens; Henning Dralle
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-01       Impact factor: 3.478

View more
  4 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 3.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

Review 4.  RET codon 609 mutations: a contribution for better clinical managing.

Authors:  Caterina Mian; Paola Sartorato; Susi Barollo; Mariangela Zane; Giuseppe Opocher
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.